-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are benefits to intravenous thrombolysis (IVT) (bridging therapy) before endovascular therapy (EVT), but there are also potential risks.
Based on this, three randomized clinical trials have recently been conducted in Asia to evaluate whether the potential risks and increased costs of IVT before EVT are reasonable for stroke patients within 4.
5 hours of onset.
The current pooled analysis mainly focuses on the data of two of the trials, aiming to evaluate the non-inferiority of EVT alone and bridging therapy in patients with large vessel occlusive stroke who are eligible for IVT.
The research results will be announced at the ME II.
Thursday Main Event of the 2021 International Stroke Conference (ISC2021).
Author: Medical team doctors report NMT NMT ISC finishing compiler, please do not reprint without authorization.
Study Introduction The SHRINE collaborative study compiled patient data from the DEVT trial in my country and the SKIP trial in Japan from February 2017 to May 2020.
To evaluate the functionally independent primary outcome and to reduce the disability-defined secondary outcome (90-day mRS score) of patients in the combined cohort; and to evaluate the heterogeneity of the results in the pre-specified subgroups.
After adjusting for age, gender, baseline NIHSS, pre-onset MRS, occlusion location, baseline ASPECTS, collateral grading, and time from onset to randomization, a mixed effects regression model was used to evaluate the common odds ratio of the primary and secondary outcomes in the overall population.
(COR).
The main research results are shown in the figure below.
Conclusion Because the adjusted OR value of the 90-day functionally independent outcome exceeds the non-inferiority threshold (0.
85) defined in the study, the study cannot determine whether EVT alone is not inferior to bridging therapy.Yimaitong compiled from: Systemic Thrombolysis Randomization In Endovascular Stroke Therapy (SHRINE) Collaboration.
ISC2021.
Lock on the medlive-neurology channel (medlive-neurology) to view the latest information of ISC 2021 simultaneously! Yimaitong ISC2021 special report long press If you follow ☟☟☟, you can also click "Read the original text" to see more ISC 2021 topic related content!
Based on this, three randomized clinical trials have recently been conducted in Asia to evaluate whether the potential risks and increased costs of IVT before EVT are reasonable for stroke patients within 4.
5 hours of onset.
The current pooled analysis mainly focuses on the data of two of the trials, aiming to evaluate the non-inferiority of EVT alone and bridging therapy in patients with large vessel occlusive stroke who are eligible for IVT.
The research results will be announced at the ME II.
Thursday Main Event of the 2021 International Stroke Conference (ISC2021).
Author: Medical team doctors report NMT NMT ISC finishing compiler, please do not reprint without authorization.
Study Introduction The SHRINE collaborative study compiled patient data from the DEVT trial in my country and the SKIP trial in Japan from February 2017 to May 2020.
To evaluate the functionally independent primary outcome and to reduce the disability-defined secondary outcome (90-day mRS score) of patients in the combined cohort; and to evaluate the heterogeneity of the results in the pre-specified subgroups.
After adjusting for age, gender, baseline NIHSS, pre-onset MRS, occlusion location, baseline ASPECTS, collateral grading, and time from onset to randomization, a mixed effects regression model was used to evaluate the common odds ratio of the primary and secondary outcomes in the overall population.
(COR).
The main research results are shown in the figure below.
Conclusion Because the adjusted OR value of the 90-day functionally independent outcome exceeds the non-inferiority threshold (0.
85) defined in the study, the study cannot determine whether EVT alone is not inferior to bridging therapy.Yimaitong compiled from: Systemic Thrombolysis Randomization In Endovascular Stroke Therapy (SHRINE) Collaboration.
ISC2021.
Lock on the medlive-neurology channel (medlive-neurology) to view the latest information of ISC 2021 simultaneously! Yimaitong ISC2021 special report long press If you follow ☟☟☟, you can also click "Read the original text" to see more ISC 2021 topic related content!
